Efficacy of copper nanoparticles encapsulated in soya lecithin liposomes in treating breast cancer cells (MCF-7) in vitro.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 09 2023
20 09 2023
Historique:
received:
05
06
2023
accepted:
11
09
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Cancer is one of the leading causes of death, which has attracted the attention of the scientific world to the search for efficient methods for treatment. With the great development and regeneration of nanotechnology over the last 25 years, various nanoparticles in different structures, shapes and composites provide good potential for cancer therapy. There are several drugs approved by FDA used in breast cancer treatment like Cyclophosphamide, Doxorubicin Hydrochloride, Femara, Herceptin, etc. Each has several side effects as well as treatment, which limits the use of drugs due to heart failure, pulmonary dysfunction, or immunodeficiency. Recently, such side effects are greatly reduced by using innovative delivery techniques. Some drugs have been approved for use in cancer treatment under the concept of drug delivery, such as Doxil (liposomal loaded doxorubicin). The purpose of this study is to investigate the effect of copper nanoparticles (CuNPs) as a drug model for cancer treatment, either in their free form or encapsulated in Soy lecithin liposomes (SLP) from plant origin as a cheap source of lipids. CuNPs were prepared by the chemical reduction method and loaded onto SLP through the thin film hydration method. The drug model Cu/SLP was successfully combined. The characteristics of the free CuNPs, liposomes, and the combined form, zeta potential, size distribution, drug encapsulation efficiency (EE%), drug release profile, Fourier transform infrared (FTIR), and transmission electron microscopy (TEM), were checked, followed by an in vitro study on the breast cancer cell line Mcf-7 as a model for cytotoxicity evaluation. The optimal Cu/SLP had a particle mean size of 81.59 ± 14.93 nm, a negative zeta potential of - 50.7 ± 4.34 mV, loaded CuNPs showed an EE% of 78.9%, a drug release profile for about 50% of the drug was released after 6 h, and FTIR analysis was recorded. The cytotoxicity assay showed that the IC
Identifiants
pubmed: 37730859
doi: 10.1038/s41598-023-42514-2
pii: 10.1038/s41598-023-42514-2
pmc: PMC10511430
doi:
Substances chimiques
Liposomes
0
Copper
789U1901C5
Lecithins
0
liposomal doxorubicin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15576Informations de copyright
© 2023. Springer Nature Limited.
Références
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
Colloids Surf B Biointerfaces. 2015 Oct 1;134:287-94
pubmed: 26209779
Pharm Dev Technol. 2020 Apr;25(4):397-407
pubmed: 31893979
J Biomed Opt. 2012 Jul;17(7):076023
pubmed: 22894506
Int J Pharm. 2015 Nov 10;495(1):329-335
pubmed: 26325307
Methods Mol Biol. 2017;1530:3-12
pubmed: 28150193
Colloids Surf B Biointerfaces. 2014 Nov 1;123:345-63
pubmed: 25280609
Nanomedicine. 2012 Feb;8(2):147-66
pubmed: 21703993
PLoS One. 2013 Aug 05;8(8):e69534
pubmed: 23940521
Cancer Biol Med. 2020 Feb 15;17(1):60-75
pubmed: 32296587
Saudi Pharm J. 2010 Oct;18(4):217-24
pubmed: 23960730
Int J Biomater. 2017;2017:8234712
pubmed: 28331495
J Breast Cancer. 2013 Jun;16(2):164-70
pubmed: 23843848
Mater Sci Eng C Mater Biol Appl. 2021 Feb;121:111832
pubmed: 33579470
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Food Funct. 2017 Nov 15;8(11):3964-3969
pubmed: 28972217
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
J Biomed Nanotechnol. 2011 Aug;7(4):489-503
pubmed: 21870454
Chem Rev. 2014 Apr 9;114(7):3659-853
pubmed: 24588098
Pharmaceutics. 2021 May 11;13(5):
pubmed: 34064746
J Invest Dermatol. 2016 Jan;136(1):e1-e7
pubmed: 26763463
Pharm Dev Technol. 2019 Feb;24(2):235-242
pubmed: 29561210
BMC Biotechnol. 2014 Mar 27;14:23
pubmed: 24674107
Biochim Biophys Acta. 2012 Jul;1818(7):1785-93
pubmed: 22503863
Materials (Basel). 2019 Sep 13;12(18):
pubmed: 31540255
J Trace Elem Med Biol. 2020 Jul;60:126481
pubmed: 32135445
Scientifica (Cairo). 2016;2016:5464373
pubmed: 27433374
Appl Microbiol Biotechnol. 2014 Feb;98(3):1001-9
pubmed: 24305741
J Biomater Appl. 2015 Jul;30(1):3-16
pubmed: 25823898
Drug Deliv Transl Res. 2016 Feb;6(1):67-72
pubmed: 26679196
Lancet Reg Health Am. 2022 Sep;13:None
pubmed: 36189115
Biomedicines. 2021 Jan 26;9(2):
pubmed: 33530291
Pharmaceutics. 2022 Mar 14;14(3):
pubmed: 35336014
Cancer Treat Rev. 2009 Feb;35(1):32-46
pubmed: 18774652
Food Res Int. 2014 Oct;64:492-499
pubmed: 30011679
Nanomedicine (Lond). 2017 Feb;12(4):357-385
pubmed: 28078952
Science. 2022 Mar 18;375(6586):1254-1261
pubmed: 35298263
Sci Rep. 2019 Aug 30;9(1):12613
pubmed: 31471546
Sci Rep. 2023 May 12;13(1):7739
pubmed: 37173419
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Molecules. 2020 Jan 28;25(3):
pubmed: 32012912